Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target

Arcutis Biotherapeutics reported a robust financial performance in the third quarter of 2025, with Zoryve generating sales of $99.2 million, reflecting a quarter-over-quarter increase of 22% and a year-over-year growth of 122%, significantly surpassing expectations. The company also announced positive net income for the first time and provided an initial sales guidance for 2026 between $455 million and $470 million, exceeding market expectations of $438.8 million. The anticipated growth is supported by the ongoing collaboration with Kowa and recent label expansions, which are expected to drive sales momentum for Zoryve through the remainder of 2025 and into 2026.

Arcutis Biotherapeutics Inc. faces significant financial challenges as it navigates the development and commercialization of its dermatological treatments, particularly with rising operating expenses anticipated in the coming years. Although the company maintains a sales guidance of $455 million to $470 million for 2026, cash reserves have dwindled to approximately $191 million after a notable reduction in net operating cash usage, indicating potential liquidity concerns. Additionally, reliance on a third-party manufacturer, Interquim, introduces further risk in the supply chain, which could adversely impact the rollout and profitability of its key product, ZORYVE.